// App-Quantinova.ai

4703 : The BET inhibitor BAY 1238097 shows efficacy in BRAF wild-type and mutant melanoma models

Researchers

Presenter

  • Bernard Haendler

Principal Investigators

  • Kathy A. Gelato

  • Laura Schockel

  • Tatsuo Sugawara

  • Pascale Lejeune

  • Heidrun Ellinger-Ziegelbauer

  • Amaury E. Fernandez-Montalvan

  • Simon Holton

  • Stephan Siegel

  • Melanie Heroult

  • Annette Walter

  • Stuart Ince

  • Matthias Ocker

Medical Centers

  • Bayer Pharma AG, Berlin, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Melanoma

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • cMYC

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved